Ameriprise
IRMD icon

Ameriprise’s iRadimed IRMD Stock Holding History

Ameriprise’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$734K Buy
7,622
+2,757
+57% +$276K ﹤0.01% 3428
2025
Q4 		$473K Buy
4,865
+61
+1% +$5.23K ﹤0.01% 3644
2025
Q3 		$342K Buy
4,804
+32
+0.7% +$2.13K ﹤0.01% 3753
2025
Q2 		$285K Sell
4,772
-1,085
-19% -$59.5K ﹤0.01% 3711
2025
Q1 		$307K Sell
5,857
-12,268
-68% -$689K ﹤0.01% 3669
2024
Q4 		$997K Buy
18,125
+1,792
+11% +$94.3K ﹤0.01% 3234
2024
Q3 		$821K Buy
16,333
+6,615
+68% +$305K ﹤0.01% 3297
2024
Q2 		$427K Sell
9,718
-2,169
-18% -$92.2K ﹤0.01% 3469
2024
Q1 		$523K Sell
11,887
-197
-2% -$8.71K ﹤0.01% 3398
2023
Q4 		$574K Buy
12,084
+126
+1% +$5.3K ﹤0.01% 3405
2023
Q3 		$531K Sell
11,958
-185
-2% -$8.6K ﹤0.01% 3392
2023
Q2 		$580K Sell
12,143
-8,072
-40% -$364K ﹤0.01% 3383
2023
Q1 		$795K Buy
20,215
+3,216
+19% +$117K ﹤0.01% 3251
2022
Q4 		$481K Buy
16,999
+3,499
+26% +$100K ﹤0.01% 3424
2022
Q3 		$406K Sell
13,500
-136
-1% -$4.74K ﹤0.01% 3468
2022
Q2 		$463K Sell
13,636
-6,698
-33% -$240K ﹤0.01% 3421
2022
Q1 		$912K Buy
+20,334
New +$940K ﹤0.01% 3252
2018
Q3 		– Sell
-288,566
Closed -$5.99M – 3753
2018
Q2 		$5.99M Sell
288,566
-181,816
-39% -$3.21M ﹤0.01% 2122
2018
Q1 		$6.63M Buy
470,382
+2,400
+0.5% +$34.2K ﹤0.01% 1970
2017
Q4 		$7.09M Buy
467,982
+11,172
+2% +$142K ﹤0.01% 1880
2017
Q3 		$4.39M Buy
456,810
+113,190
+33% +$1.07M ﹤0.01% 2177
2017
Q2 		$2.95M Buy
+343,620
New +$2.93M ﹤0.01% 2411
2017
Q1 		– Sell
-74,500
Closed -$827K – 3644
2016
Q4 		$827K Buy
74,500
+9,300
+14% +$100K ﹤0.01% 3047
2016
Q3 		$1.11M Buy
65,200
+5,370
+9% +$99.4K ﹤0.01% 2876
2016
Q2 		$1.3M Buy
59,830
+530
+0.9% +$9.54K ﹤0.01% 2757
2016
Q1 		$1.14M Buy
59,300
+24,105
+68% +$461K ﹤0.01% 2791
2015
Q4 		$987K Buy
+35,195
New +$995K ﹤0.01% 2968

Other funds holding IRMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise's IRMD Position: Q1 2026 in Review

Ameriprise increased its iRadimed (IRMD) stake by 57% in Q1 2026, buying an estimated $276K and bringing the position to 7,622 shares worth $734K. The position accounts for ﹤0.01% of the portfolio, ranked #3428.

Ameriprise first reported a position in IRMD in Q4 2015 and has held it in 27 quarters since. The position peaked at $7.09M in Q4 2017. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

  • Ameriprise held 7,622 shares of iRadimed worth $734K as of Q1 2026.
  • Ameriprise bought 2,757 iRadimed shares in Q1 2026, an estimated $276K.
  • iRadimed made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3428 holding.
  • Ameriprise first reported a position in iRadimed in Q4 2015 and has held it in 27 quarters since.
  • Ameriprise's iRadimed position peaked at $7.09M in Q4 2017.
  • 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.